These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36460471)

  • 1. Economic Evaluation of the Community Benefit of the Australian Pregnancy Register of Antiseizure Medications.
    Ademi Z; Marquina C; Perucca P; Hitchcock A; Graham J; Eadie MJ; Liew D; O'Brien TJ; Vajda FJ
    Neurology; 2023 Mar; 100(10):e1028-e1037. PubMed ID: 36460471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projected Return on Investment From Implementation of a Lifestyle Intervention to Reduce Adverse Pregnancy Outcomes.
    Lloyd M; Teede H; Bailey C; Callander E; Ademi Z
    JAMA Netw Open; 2022 Sep; 5(9):e2230683. PubMed ID: 36066890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia.
    Marquina C; Ademi Z; Zomer E; Ofori-Asenso R; Tate R; Liew D
    J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105931. PubMed ID: 34157669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost-effectiveness and return on investment of the Victorian Cardiac Outcomes Registry in Australia: a minimum threshold analysis.
    Lee P; Brennan AL; Stub D; Dinh DT; Lefkovits J; Reid CM; Zomer E; Liew D
    BMJ Open; 2023 Apr; 13(4):e066106. PubMed ID: 37185178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28).
    Lee P; Zomer E; Liew D
    Heart Lung Circ; 2020 Jul; 29(7):1046-1053. PubMed ID: 31537440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
    Marklund M; Zheng M; Veerman JL; Wu JHY
    PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
    Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of future skin cancer prevention in Australia.
    Shih ST; Carter R; Heward S; Sinclair C
    Prev Med; 2017 Jun; 99():7-12. PubMed ID: 28131778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of the Cost-Effectiveness of Lifestyle Interventions in Pregnancy.
    Bailey C; Skouteris H; Harrison CL; Hill B; Thangaratinam S; Teede H; Ademi Z
    Value Health; 2022 Feb; 25(2):194-202. PubMed ID: 35094792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry programme-subanalyses for Māori (ANZACS-QI 42).
    Lee P; Zomer E; Liew D
    N Z Med J; 2020 May; 133(1514):16-32. PubMed ID: 32379736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy, antiseizure medications and unexplained intrauterine foetal death.
    Vajda FJE; O'Brien TJ; Graham JE; Hitchcock AE; Perucca P; Lander CM; Eadie MJ
    Epilepsy Behav; 2024 Apr; 153():109724. PubMed ID: 38442517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions.
    Gumbie M; Parkinson B; Cutler H; Gauld N; Mumford V
    Pharmacoeconomics; 2019 Aug; 37(8):1049-1064. PubMed ID: 31069781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of clinical quality registries: a systematic review.
    Lee P; Chin K; Liew D; Stub D; Brennan AL; Lefkovits J; Zomer E
    BMJ Open; 2019 Dec; 9(12):e030984. PubMed ID: 31843824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of population-based, expanded reproductive carrier screening for genetic diseases in Australia.
    Schofield D; Lee E; Parmar J; Kelly S; Hobbs M; Laing N; Mumford J; Shrestha R
    Genet Med; 2023 May; 25(5):100813. PubMed ID: 36789890
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.